MBX Biosciences, Inc.
MBXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Valued at $2.69B, MBX is a mid-cap name in its sector. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Market Cap
$2.69B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-14.40
EPS (TTM)
$-2.04
EPS (Fwd)
$-3.93
ROE
-25.7%
ROA
-17.7%
Cash
$440.0M
Total Debt
$555,000
Free CF
-$52.5M
52W Change
348.1%
Annual Financials
Cash vs Debt
MBX Biosciences, Inc. holds $440.0M in cash against $555K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$52.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -25.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MBX Biosciences, Inc.'s trajectory.